中文
EN
About us
Company Introduction
Corporate History
Business Introduction
Corporate Governance
Company Culture
Corporate Honors
R&D and Innovation
R&D
Innovation
Product Pipeline
Achievements
Products
Drug Products
Biological products
APIs
Intermediates
Boranes
OLED Materials
CDMO
Project Collaboration
In-/Out-Licensing
Joint Venture
Sustainable
EHS
Energy
Quality
Supplier
News Center
2024
2023
2022
2021
Join Us
Talent Philosophy
Talent Development
Salary and Benefits
Campus Recruiting
Social Recruitment
Contact Us
Online Message
Blog Center
In 2024
In 2023
In 2022
In 2021
In 2020
In 2019
In 2018
In 2017
In 2016
Viwit Pharmaceutical's Phenylephrine Hydrochloride Injection Officially Receives Official Approval by China NMPA
Viwit Pharmaceuticals’ Brimonidine tartrate and Timolol maleate eye drops receive Official Approval by China NMPA
Viwit's Nitroglycerin Sublingual Tablets Approved by FDA
Viwit Pharmaceuticals API Site Successfully Passed FDA cGMP On-site Audit with "No Action Indicated"
Viwit Pharmaceutical Co. Ltd. announces exclusive licensing and supply agreement for two Gadolinium based Magnetic Resonance Imaging (MRI) injectable contrast agents in the US.
Viwit Pharmaceutical’s Lifitegrast API has completed registrations in both China and the US!
Viwit Pharmaceuticals' Aprepitant API Receives Official Approval by China NMPA
On October 26, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by China National Medical Products Administration (NMPA) for the independently developed active pharmaceutical ingredient (API) Aprepitant. The registration number is Y20210000473, and the notice number is 2023YS00727.
31
/
10
Viwit Pharmaceuticals obtained the Drug Production License C
Congratulations to Viwit Pharmaceuticals that Viwit obtained the Drug Production License C for solid preparations and injections on July 28th, 2023. Meaning, that Viwit’s production lines for solid preparations and injections own the qualification on contracted manufacturing.
30
Viwit Pharmaceuticals’BFS Technology
Viwit’s sterile blow-fill-seal (BFS) eye drops manufacturing facility is established in 2021. The BFS production line fulfills the need for an advanced aseptic manufacturing process using the state of the art Rommelag 434 BFS system. Pharmaceutical grade low-density polyethylene (PE) is used to ensure product quality and prevent leachable and leakage. A strip of 15 doses attached to each other can be created and filled within a few seconds. Every single BFS ampule is detected for leakage to ensure the integrity of the dose.
18
Meeting Viwit Pharmaceuticals at CPHI Barcelona
Viwit Pharmaceuticals will be participating in CPHI Barcelona 2023 in Oct. 24th~26th, 2023 at Fira Barcelona Gran Via, Spain. Welcome to visit our booth 7D30 or contact us to learn more about our full portfolio of products, services, and solutions. We look forward to seeing you soon!
09
SST Corporation and Viwit Pharmaceuticals Establish Strategic Collaboration
Having become an officially qualified API/CMC supplier to SST Corporation, Viwit and SST have established a strategic collaboration aiming to promote small molecule pharmaceutical contract development and manufacturing organization (CDMO) services in North America.
11
08
Viwit Pharmaceutical Invites You to Meet at CPHI North America
Viwit Pharmaceuticals will be participating in the CPHI North America conference this year from April 25- 27,2023 at Pennsylvania Convention Center, in Philadelphia. Welcome to stop by our booth # 1114 and explore how our CDMO services and solutions would benefit your drug development and manufacturing pipeline. We are looking forward to meeting and collaborating with you in the heart of the US pharma Industry!
01
03
Viwit Pharmaceutical Is Now Officially GMP Certified by South Korean MFDS
Shandong, February 13, 2023 -- Viwit Pharmaceutical, an innovation-driven global company providing CDMO services to pharmaceutical and biotech industries, successfully passed the GMP inspection and approved by the South Korean regulatory agency, the Ministry of Food and Drug Safety (MFDS).
27
02
Viwit Pharmaceutical Co., Ltd. participated in CPHI Worldwide 2022 held in Frankfurt Germany from November 1st to November 3rd.
As the world's largest pharmaceutical industry exhibition, CPHI has been successfully held for 30 years. It displays the entire pharmaceutical supply chain, from API, P-MEC to FDF. It becomes the largest annual gathering of pharmaceutical professionals all over the world. Viwit met old friends and new business partners at CPHI. We displayed a wonderful enterprise image with our products and services, and promoted our international business through CPHI.
Search